Comparative Evaluation of Linezolid and Teicoplanin in the Treatment of Ventilator-Associated MRSA Pneumonia: A Single-Center Experience
| Author | Md Jahidul Hasan | en |
| Author | Shahzadi Sayeeda Tun Nessa | en |
| Author | Raihan Rabbani | en |
| Orcid | Md Jahidul Hasan [0000-0001-7038-6437] | en |
| Orcid | Raihan Rabbani [0000-0001-5173-5793] | en |
| Issued Date | 2020-07-31 | en |
| Abstract | Background: Ventilator-associated pneumonia (VAP) caused by methicillin-resistant Staphylococcus aureus (MRSA) is a serious infection in an intensive care unit (ICU). Ventilator-associated MRSA pneumonia (VAMP) in critically ill patients causes a high rate of mortality. Objectives: This study mainly aimed to compare the clinical outcomes and associated drug safety perspective of linezolid and teicoplanin in VAMP treatment. Methods: This retrospective study included 98 adult ICU patients with VAMP, where 42 patients (LZD group) and 56 patients (TPN group) received a standard dose of linezolid and teicoplanin, respectively, for their VAMP treatment. Adverse reactions associated with linezolid and teicoplanin were considered. Clinical outcomes and 30-day mortality rates were compared in both groups. Results: The LZD group showed a higher MRSA eradication rate (97%, n = 34) than the TPN group (94.3%, n = 53) (P = 0.034). The linezolid and teicoplanin therapy was suddenly discontinued in 19% and 5.3% of the patients in the LZD and TPN groups, respectively, before completing the full duration of antibiotic therapy due to developed adverse drug reactions (ADRs), including thrombocytopenia (LZD/TPN groups: 7/1 event), tachycardia (LZD group: 1 event), and nephrotoxicity (TPN group: 2 events). This discontinuation increased the total duration of antibiotic therapy in 19% (n = 42) and 5.3% (n = 56) of the patients (P = 0.034) in the LZD and TPN groups, respectively. Conclusions: VAMP is a life-threatening event in critically ill ICU patients worldwide. In this study, teicoplanin showed better clinical outcomes with a certain higher level of drug safety compared to linezolid in the treatment of ventilator-associated MRSA pneumonia. | en |
| DOI | https://doi.org/10.5812/iji.104447 | en |
| Keyword | Ventilator-Associated Pneumonia | en |
| Keyword | Methicillin-Resistant <i>Staphylococcus aureus</i> | en |
| Keyword | Linezolid | en |
| Keyword | Teicoplanin | en |
| Keyword | Adverse Drug Reaction | en |
| Keyword | Critically Ill Patients | en |
| Publisher | Brieflands | en |
| Title | Comparative Evaluation of Linezolid and Teicoplanin in the Treatment of Ventilator-Associated MRSA Pneumonia: A Single-Center Experience | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- iji-7-3-104447.pdf
- Size:
- 148.12 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF